Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018

Including Three Late-Breaking Poster Presentations

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies of its Lm-based antigen delivery technology will be presented at the American Association for Cancer Research Annual Meeting 2018 (AACR 2018), April 14-18, 2018 in Chicago.

The following late-breaking research will be presented:

Poster Title:

        
        
        
        
        
        
        
        
          Neoantigens that fail to elicit measurable T cell responses 
          following peptide immunization can control tumor growth when 
          delivered using a Listeria-based immunotherapy platform
        
      
      
        
          

Poster Number:

        
        
        
        
        
        
        
        
          LB-150/17
        
      
      
        
          

Session Title:

        
        
        
        
        
        
        
        
          Late-Breaking Research: Clinical Research
        
      
      
        
          

Session Date and Time:

        
        
        
        
        
        
        
        
          Monday, April 16, 2018, 1:00 pm - 5:00 pm (CT)
        
      
      
        
          

Authored By:

        
        
        
        
        
        
        
        
          Advaxis and Amgen
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
    
    
      
        
        
        
           
        
        
           
        
        
           
        
        
        
      
      
        
          

Poster Title:

Targeting frameshift mutations with a Listeria monocytogenes immunotherapy drives neoantigen-specific antitumor immunity in the MC38 and CT26 mouse tumor models

Poster Number:

        
        
        
        
        
        
        
        
          LB-148/15
        
      
      
        
          

Session Title:

        
        
        
        
        
        
        
        
          Late-Breaking Research: Clinical Research
        
      
      
        
          

Session Date and Time:

        
        
        
        
        
        
        
        
          Monday, April 16, 2018, 1:00 pm - 5:00 pm (CT)
        
      
      
        
          

Authored By:

        
        
        
        
        
        
        
        
          Advaxis and Amgen
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
    
    
      
        
        
        
           
        
        
           
        
        
           
        
        
        
      
      
        
          

Poster Title:

Targeting shared hotspot cancer mutations with a Listeria monocytogenes immunotherapy induces potent anti-tumor immunity

Poster Number:

        
        
        
        
        
        
        
        
          LB-149/16
        
      
      
        
          

Session Title:

        
        
        
        
        
        
        
        
          Late-Breaking Research: Clinical Research
        
      
      
        
          

Session Date and Time:

        
        
        
        
        
        
        
        
          Monday, April 16, 2018, 1:00 pm - 5:00 pm (CT)
        
      
      
        
          

Authored By:

        
        
        
        
        
        
        
        
          Advaxis
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
    
    

In addition, the following Investigator Sponsored Trial data will be presented:

Poster Title:

        
        
        
        
        
        
        
        
          Changes in local and peripheral T cell diversity after HPV E7 
          antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior 
          to robotic surgery for HPV-positive oropharyngeal cancer
        
      
      
        
          

Poster Number:

        
        
        
        
        
        
        
        
          5639/10
        
      
      
        
          

Session Title:

        
        
        
        
        
        
        
        
          PO.CL06.11: Vaccines 2
        
      
      
        
          

Session Date and Time:

        
        
        
        
        
        
        
        
          Wednesday, April 18, 2018, 8:00 am - 12:00 pm (CT)
        
      
      
        
          

Authored By:

        
        
        
        
        
        
        
        
          Andrew Sikora, Ph.D., MD, co-director of the Head and Neck Cancer 
          Program at Baylor College of Medicine
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
    
    

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, neoantigen therapy, hotspot/ cancer antigens and prostate cancer.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube.

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2017, and on Form 10-Q for the quarter ended January 31, 2018, which are available at www.sec.gov.

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180326005188/en/

Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr. Director Corporate Communications and Government [e-mail]:Stern Strategy GroupBrian Hyland, [e-mail] Auerbach, [e-mail]:LHA Investor RelationsAnne Marie Fields, [e-mail]